James Brumley

James Brumley

James Brumley is a reformed stock broker and former Director of Research for an options-focused newsletter. He’s now primarily a freelance writer, tapping more than a decade’s worth of broad experience to help investors get more out of the market.

With a background in technical analysis as well as fundamental analysis, James writes with a multifaceted philosophy that combines the importance of company performance with the power of stock-trade timing. His commentary is as apt to focus on a chart as it is earnings, as he believes this dual approach is the only way an investor has a shot at consistently beating the market.

James’ work has appeared at several websites, including Street Authority, Motley Fool, Kapitall and Investopedia. When not writing as a journalist, James works on his book explaining his multipronged approach to investing.

Recent Articles

Twitter: Great Story or Not, TWTR Stock Has a Valuation Problem

Twitter might be all the rage, but that doesn't necessarily make TWTR stock a good investment. Its way-too-frothy price is impossible to justify.

Horrible Bosses – The Worst 5 CEOs of 2013

These five execs have left behind an ugly legacy, qualifying them as the worst CEOs of 2013. Unfortunately, some of them are still around to do more damage.

5 ‘Problem’ Stocks to Avoid in 2014

While 2014 should be a decent year for the broader markets, you might be better off shirking these five stocks to avoid until things significantly change for each.

Gun Sales Spike Puts Pressure on Smith & Wesson, Ruger

SWHC and RGR have had a great run, thanks to fear of stricter laws prodding gun sales. That was a once-in-a-decade prod, however, meanings the next few years could be lackluster.

5 Pharma Stocks to Buy for Big Dividends

Drugmakers aren't known for big dividends, but the pharmaceutical industry can actually offer something for income investors.